216 related articles for article (PubMed ID: 17169767)
1. Osteonecrosis of the jaws in patients with bone metastasis receiving intravenous bisphosphonates. A rising concern.
Aguiar Bujanda D; Cabrera Suárez MA; Bohn Sarmiento U; Quintero Pérez S; Aguiar Morales J
Clin Transl Oncol; 2006 Dec; 8(12):919-21. PubMed ID: 17169767
[TBL] [Abstract][Full Text] [Related]
2. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis.
Aguiar Bujanda D; Bohn Sarmiento U; Cabrera Suárez MA; Aguiar Morales J
Ann Oncol; 2007 Mar; 18(3):556-60. PubMed ID: 17082512
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates and osteonecrosis of the jaw: a case report.
Reiriz AB; De Zorzi Pde M; Lovat CP
Clinics (Sao Paulo); 2008 Apr; 63(2):281-4. PubMed ID: 18438586
[No Abstract] [Full Text] [Related]
4. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
[TBL] [Abstract][Full Text] [Related]
5. Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
La Verde N; Bareggi C; Garassino M; Borgonovo K; Sburlati P; Pedretti D; Bianchi C; Perrone S; Mihali D; Cobelli S; Mantica C; Rizzo A; Farina G
Support Care Cancer; 2008 Nov; 16(11):1311-5. PubMed ID: 18663482
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate-related osteonecrosis of the jaws--report of 2 cases and strategies on prevention and management.
Wong YK; Cheng JC
Quintessence Int; 2008 Mar; 39(3):195-201. PubMed ID: 18618033
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
9. [Avascular osteonecrosis of the jaws induced by diphosphonates].
Lannoy D; Decaudin B; Barrier F; Bemba M; Wierre L; Pignon JM; Horrent S; Résibois JP; Wetterwald M; Odou P
Therapie; 2006; 61(4):363-5. PubMed ID: 17124954
[No Abstract] [Full Text] [Related]
10. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
Van Poznak C; Estilo C
Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349
[TBL] [Abstract][Full Text] [Related]
11. The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer.
Van Poznak C
Cancer Invest; 2006 Feb; 24(1):110-2. PubMed ID: 16467002
[TBL] [Abstract][Full Text] [Related]
12. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA
Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma.
Diego R; D'Orto O; Pagani D; Agazzi A; Marzano U; Derada Troletti G; Fontanella W; Pignataro L
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103(3):e1-5. PubMed ID: 17197204
[TBL] [Abstract][Full Text] [Related]
14. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.
Ortega C; Montemurro F; Faggiuolo R; Vormola R; Nanni D; Goia F; Gilardino MO; Aglietta M
Acta Oncol; 2007; 46(5):664-8. PubMed ID: 17562443
[TBL] [Abstract][Full Text] [Related]
15. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
Tosi P; Zamagni E; Cangini D; Tacchetti P; Di Raimondo F; Catalano L; D'Arco A; Ronconi S; Cellini C; Offidani M; Perrone G; Ceccolini M; Brioli A; Tura S; Baccarani M; Cavo M
Blood; 2006 Dec; 108(12):3951-2. PubMed ID: 17114572
[No Abstract] [Full Text] [Related]
16. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
Murad OM; Arora S; Farag AF; Guber HA
Endocr Pract; 2007; 13(3):232-8. PubMed ID: 17599853
[TBL] [Abstract][Full Text] [Related]
17. Early appearance of osteonecrosis of the jaw after zoledronic acid in a patient with a long history of taking oral bisphosphonates.
Uña E
BMJ Case Rep; 2012 Mar; 2012():. PubMed ID: 22605820
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate osteonecrosis of the jaws in cancer patients.
Kyrgidis A; Andreadis C
Breast; 2009 Oct; 18(5):335. PubMed ID: 19783147
[No Abstract] [Full Text] [Related]
19. Bisphosphonate-induced osteonecrosis of the jaws: review, clinical implications and case report.
Suleman YF; Meer S; Lurie R
Head Neck Pathol; 2007 Dec; 1(2):156-64. PubMed ID: 20614268
[TBL] [Abstract][Full Text] [Related]
20. Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.
Fusco V; Galassi C; Berruti A; Ciuffreda L; Ortega C; Ciccone G; Angeli A; Bertetto O
J Clin Oncol; 2011 Jun; 29(17):e521-2; author reply e523-4. PubMed ID: 21537047
[No Abstract] [Full Text] [Related]
[Next] [New Search]
